Chemokines are a family of small cytokines, which guide a variety of immune/inflammatory cells to the site of tumor in tumorigenesis. A dysregulated expression of chemokines is implicated in different types of cancer including prostate cancer. The progression and metastasis of prostate cancer involve a complex network of chemokines that regulate the recruitment and trafficking of immune cells. The chemokine CCL2 and its main receptor CCR2 have been receiving particular interest on their roles in cancer pathogenesis. The up-regulation of CCL2/CCR2 and varied immune conditions in prostate cancer, are associated with cancer advancement, metastasis, and relapse. Here we reviewed recent findings, which link CCL2/CCR2 to the inflammation and cancer pathogenesis, and discussed the therapeutic potential of CCL2/CCR2 axis in cancer treatment based on results from our group and other investigators, with a major focus on prostate cancer.

中文翻译：

---

CCL2/CCR2 信号在癌症发病机制中的作用。

趋化因子是一个小细胞因子家族，在肿瘤发生过程中将多种免疫/炎症细胞引导至肿瘤部位。趋化因子的失调表达与包括前列腺癌在内的不同类型的癌症有关。前列腺癌的进展和转移涉及调节免疫细胞募集和运输的复杂趋化因子网络。趋化因子 CCL2 及其主要受体 CCR2 在癌症发病机制中的作用一直受到特别关注。CCL2/CCR2 的上调和前列腺癌中不同的免疫条件与癌症进展、转移和复发有关。在这里，我们回顾了最近的发现，这些发现将 CCL2/CCR2 与炎症和癌症发病机制联系起来，